India · Delayed Price · Currency is INR Uflex Earnings Call Transcripts
Fiscal Year 2026
-
Revenue and EBITDA remained stable despite macro headwinds, with strong growth in aseptic packaging and margin expansion in Q3. Major projects are nearing commissioning, expected to drive future growth and improve leverage as utilization ramps up.
-
H1 FY2026 saw 3% sales and 4% EBITDA growth year-over-year, with PAT up 150% due to lower currency losses. Guidance for FY2026 is revised to 5% revenue growth and INR 1,800-1,850 crore EBITDA, with new projects expected to boost results in FY2027. Imports and regulatory changes continue to impact margins and industry dynamics.
-
Revenue grew 6.5% YoY to INR 3,922 crore, driven by higher volumes, though margins dipped to 12%. Expansion projects are on track, with new capacity expected to add INR 3,000 crore in revenue and INR 600 crore EBITDA. Net debt/EBITDA is set to fall below 3x as new projects ramp up.
Fiscal Year 2025
-
FY 2025 saw a strong recovery with revenue, EBITDA, and PAT all improving year-over-year, led by packaging films and aseptic packaging. FY 2026 is expected to deliver 10% revenue growth, new project commissions, and stable margins, though BOPP overcapacity may pressure pricing.
-
Q3 FY25 saw strong revenue and margin growth, with improved plant utilization and major investments in recycling and packaging. FY26 guidance points to double-digit revenue growth, margin expansion, and full ramp-up of new facilities.
-
Q2 FY25 delivered strong revenue and EBITDA growth, led by robust packaging films and aseptic packaging performance, despite margin pressures from currency devaluation and high finance costs. Capacity expansions in India and Egypt are set to drive future growth.
-
Q1 FY2025 saw strong revenue and margin growth, driven by higher BOPET/BOPP prices and robust PET chips and aseptic packaging performance. EBITDA guidance was raised, with new capacity and regulatory-driven recycling opportunities expected to boost future results.